Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,457.00    6.00 (0.41%)
Bid:
1,464.00
Ask:
1,466.00
Spread: 2.00 (0.137%)
Market Cap: £3.08b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Director/PDMR Shareholding

23 Apr 2010 15:16

RNS Number : 7219K
Hikma Pharmaceuticals Plc
23 April 2010
 



 

Annex DTR3

 

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons

 

 

All relevant boxes should be completed in block capital letters.

 

1.

Name of the issuer

 

HIKMA PHARMACEUTICALS PLC

2.

State whether the notification relates to (i) a

transaction notified in accordance with DTR 3.1.2 R,

(ii) a disclosure made in accordance

LR 9.8.6R(1) or

(iii) a disclosure made in accordance with section 793 of the Companies Act (2006).

 

(i)

 

3.

Name of person discharging managerial

responsibilities/director

 

BASSAM KANAAN

4.

State whether notification relates to a person

connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person

 

N/A

 

5.

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a nonbeneficial

interest 1

 

3 ABOVE

 

6.

Description of shares (including class), debentures or derivatives or financial instruments relating to shares

 

ORDINARY SHARES OF 10P EACH

 

7.

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them

 

BASSAM KANAAN

8.

State the nature of the transaction

 

SALE OF 30,000 NIL-COST SHARE AWARDS UNDER THE TERMS OF THE 2006 LONG TERM INCENTIVE PLAN UPON VESTING

 

AND

 

EXERCISE OF 43,582 ORDINARY SHARES AT $0.9075 PER SHARE UNDER THE TERMS OF THE 2004 STOCK OPTION PLAN

 

9.

Number of shares, debentures or financial

instruments relating to shares acquired

 

 

N/A

10.

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage)

 

N/A

 

 

11.

Number of shares, debentures or financial

instruments relating to shares disposed

 

30,000 (LTIP)

 

43,582 (STOCK OPTIONS)

12.

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)

 

0.0038%

 

13.

Price per share or value of transaction

 

£6.4268998 (LTIP)

 

£6.35 (for 13,582 STOCK OPTIONS)

 

£6.36 (for 30,000 STOCK OPTIONS)

14.

Date and place of transaction

 

22 APRIL 2010, LONDON (LTIP AND 13,582 OF STOCK OPTIONS)

 

23 APRIL (30,000 STOCK OPTIONS)

 

 

15.

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)

 

89,222 (0.046%)

16.

Date issuer informed of transaction

 

23 APRIL 2010

 

 

 

If a person discharging managerial responsibilities has been granted options by the issuer

complete the following boxes

 

17.

Date of grant

 

N/A

18.

Period during which or date on which exercisable

 

 N/A

19.

Total amount paid (if any) for grant of the option

 

N/A

20.

Description of shares or debentures involved (class and number)

 

N/A

21.

Exercise price (if fixed at time of grant) or

indication that price is to be fixed at the time of exercise

 

N/A

22.

Total number of shares or debentures over which options held following notification

 

 

N/A

23.

Any additional information

 

 

N/A

24.

Name of contact and telephone number for queries

 

Mark Duckworth 0207 399 2766

 

 

 

 

 

Name of authorised official of issuer responsible for making notification

 

Henry Knowles

 

Date of notification 23 April 2010

 

 

 

Notes: This form is intended for use by an issuer to make a RIS notification required by DR 3.3.

 

(1)

An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.

(2)

An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.

(3)

An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.

(4)

An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSBSGDSUBDBGGX
Date   Source Headline
11th Nov 202512:13 pmRNSHolding(s) in Company
11th Nov 202511:42 amRNSDirector/PDMR Shareholding
7th Nov 202512:56 pmRNSDirector/PDMR Shareholding
6th Nov 20257:00 amRNSNovember Trading Statement
1st Oct 202511:45 amRNSBlock listing Interim Review
23rd Sep 20251:52 pmRNSDirector/PDMR Shareholding
17th Sep 20259:16 amRNSDirector/PDMR Shareholding
22nd Aug 202512:02 pmRNSDirector/PDMR Shareholding
13th Aug 20251:51 pmRNSDirector/PDMR Shareholding
8th Aug 202512:59 pmRNSDirector/PDMR Shareholding
7th Aug 20257:00 amRNSHalf-year Report
9th Jul 20259:00 amRNSNotice of Results
7th Jul 20259:16 amRNSPublication of Offering Circular
9th Jun 20253:33 pmRNSDirector/PDMR Shareholding
5th Jun 20252:05 pmRNSDirector/PDMR Shareholding
3rd Jun 20251:02 pmRNSDirector/PDMR Shareholding
29th May 20257:00 amRNSFitch upgrades Hikma to ‘BBB’
20th May 20252:49 pmRNSDirector/PDMR Shareholding
15th May 202512:00 pmRNSMedium-term Group guidance ahead of US site visit
8th May 20254:35 pmRNSDirector/PDMR Shareholding
8th May 202510:48 amRNSS&P upgrades Hikma to ‘BBB’
8th May 20258:21 amRNSSettlement agreement for Xyrem® US lawsuits
30th Apr 20251:21 pmRNSDirector/PDMR Shareholding
24th Apr 20253:55 pmRNSResult of AGM
24th Apr 20257:00 amRNSTrading Statement
10th Apr 20252:36 pmRNSDirector/PDMR Shareholding
8th Apr 20251:47 pmRNSDirector/PDMR Shareholding
1st Apr 20259:30 amRNSBlock listing Interim Review
19th Mar 202510:10 amRNSAnnual Financial Report and Notice of AGM
4th Mar 202511:16 amRNSDirector/PDMR Shareholding
26th Feb 20257:00 amRNSFinal Results
10th Feb 20258:09 amRNSNotice of Results
23rd Dec 20249:46 amRNSDirector/PDMR Shareholding
7th Nov 20243:30 pmRNSOutcome of Audit Tender Process
7th Nov 20247:00 amRNSTrading Statement
24th Oct 20247:00 amRNS2024 Annual General Meeting Update Statement
1st Oct 20249:45 amRNSBlock listing Interim Review
24th Sep 202410:09 amRNSDirector/PDMR Shareholding
10th Sep 20247:00 amRNSHikma completes Xellia acquisition
13th Aug 20249:39 amRNSDirector/PDMR Shareholding
8th Aug 20247:00 amRNSHalf-year Report
29th Jul 20244:08 pmRNSDirector Declaration
15th Jul 20247:00 amRNSNotice of Results
1st Jul 20242:47 pmRNSTotal Voting Rights
27th Jun 20241:47 pmRNSDirector Declaration
17th Jun 20247:00 amRNSHikma acquires Xellia’s assets
5th Jun 20242:53 pmRNSDirector/PDMR Shareholding
9th May 20249:49 amRNSDirector/PDMR Shareholding
25th Apr 20242:28 pmRNSResult of AGM
25th Apr 20247:00 amRNSTrading Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.